Patents by Inventor Alan M. Fogelman
Alan M. Fogelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100143444Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.Type: ApplicationFiled: February 7, 2008Publication date: June 10, 2010Inventors: Gattadahalli M. Anantharamaiah, Alan M. Fogelman, Mohamad Nayab, Martin Rudolf
-
Patent number: 7723045Abstract: This invention provides novel assays for the detection of dysfunctional HDL. The assays are good diagnostics and/or prognostics for atherosclerosis or other pathologies characterized by an inflammatory response. In certain embodiments the methods involve measurements of heme-related HDL-associated proteins (e.g., haptoglobin, hemopexin, etc.), and/or measurements of the relative distribution of HDL-associated proteins between HDL and the non-lipoprotein fractions of plasma/serum, and/or measurements of the ability of pro-inflammatory HDL to consume nitric oxide, and/or measurement of the ability of HDL to inhibit LDL aggregation.Type: GrantFiled: February 8, 2007Date of Patent: May 25, 2010Assignee: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Srinivasa T. Reddy
-
Patent number: 7723303Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route.Type: GrantFiled: April 18, 2006Date of Patent: May 25, 2010Assignees: The Regents of the University of California, The UAB Research FoundationInventors: Alan M. Fogelman, Mohamad Navab, Gattadahalli M. Anantharamaiah
-
Patent number: 7638494Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.Type: GrantFiled: April 1, 2003Date of Patent: December 29, 2009Assignee: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Mohamad Navab
-
Publication number: 20090286741Abstract: The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as diverse as the brain and the kidney. This invention provides a method to improve the structure and function of arterioles and preserve the function of end organs such as the brain and kidney.Type: ApplicationFiled: June 4, 2009Publication date: November 19, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Alan M. Fogelman
-
Patent number: 7579319Abstract: The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as diverse as the brain and the kidney. This invention provides a method to improve the structure and function of arterioles and preserve the function of end organs such as the brain and kidney. In certain embodiments, the methods involve administering to a human having thickened arterioles in brain, kidney or alveoli a peptide that ranges in length up to 30 amino acids, and that comprises a class A amphipathic helix, and bears at least one protecting group.Type: GrantFiled: December 6, 2005Date of Patent: August 25, 2009Assignee: The Regents of the University of CaliforniaInventor: Alan M. Fogelman
-
Publication number: 20090163408Abstract: This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues when orally administered in conjunction with a peptide pharmaceutical (e.g., a class A amphipathic helical peptide as described herein) significantly increases the bioavailability of that peptide. Methods of peptide delivery using such “delivery agents” and pharmaceutical formulations are provided.Type: ApplicationFiled: August 7, 2007Publication date: June 25, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Alan M. Fogelman, Mohamad Navab
-
Patent number: 7531514Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. In certain embodiments, the peptides comprise an 18 amino acid class A amphipathic helix with protecting groups on the amino and the carboxyl terminus. The peptides are highly stable, readily administered via an oral route, and effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles, and/or to promote lipid transport and detoxification. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.Type: GrantFiled: May 9, 2006Date of Patent: May 12, 2009Assignees: The Regents of the University of California, The UAB Research FoundationInventors: Alan M. Fogelman, Gattadahalli M. Anantharamaiah, Mohamad Navab
-
Publication number: 20080293639Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route.Type: ApplicationFiled: December 4, 2007Publication date: November 27, 2008Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: ALAN M. FOGELMAN, MOHAMAD NAVAB
-
Patent number: 7250304Abstract: This invention provides novel assays that are prognostic and/or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e.g., lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and/or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.Type: GrantFiled: February 7, 2005Date of Patent: July 31, 2007Assignee: The Regents of the University of CaliforniaInventors: Alan M Fogelman, Mohamad Navab, Susan Hama
-
Patent number: 7199102Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides typically range in length up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.Type: GrantFiled: April 25, 2003Date of Patent: April 3, 2007Assignee: The Regents of the University of CaliforniaInventors: Alan M Fogelman, Gattadahalli M Anantharamaiah, Mohamad Navab
-
Patent number: 7166578Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages. In certain embodiments, the peptides range in length from about 10 up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent.Type: GrantFiled: October 16, 2002Date of Patent: January 23, 2007Assignees: The Regents of the University of California, The University of Alabama Research FoundationInventors: Alan M Fogelman, Gattadahalli M Anantharamaiah, Mohamad Navab
-
Patent number: 7148197Abstract: This invention provides novel peptides for the treatment of atherosclerosis.Type: GrantFiled: August 26, 2003Date of Patent: December 12, 2006Assignees: The Regents of the University of California, The University of Alabama Research FoundationInventors: Alan M Fogelman, Gattadahalli M Anantharamaiah, Mohamad Navab
-
Patent number: 7144862Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. In certain embodiments, the peptide comprises an amino acid sequence that ranges in length from about 10 up to about 30 amino acids, that comprises at least one class A amphipathic helix, that bears at least one protecting group, that protects a phospholipid against oxidation by an oxidizing agent; and that is not the D-18A peptide. The peptides are highly stable and readily administered via an oral route.Type: GrantFiled: June 28, 2002Date of Patent: December 5, 2006Assignees: The Regents of the University of California, The University of Alabama Research FoundationInventors: Alan M. Fogelman, Gattadahalli M. Anantharamaiah, Mohamad Navab
-
Patent number: 6933279Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route.Type: GrantFiled: June 29, 2001Date of Patent: August 23, 2005Assignee: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Gattadahalli M. Anantharamaiah, Mohamad Navab
-
Patent number: 6930085Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.Type: GrantFiled: April 5, 2002Date of Patent: August 16, 2005Assignee: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Mohamad Navab
-
Patent number: 6869568Abstract: This invention provides novel assays that are prognostic and/or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e.g. lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and/or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.Type: GrantFiled: June 5, 2003Date of Patent: March 22, 2005Assignee: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Mohamad Navab, Susan Hama
-
Publication number: 20040266671Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.Type: ApplicationFiled: April 25, 2003Publication date: December 30, 2004Applicant: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Gattadahalli M. Anantharamaiah, Mohamad Navab
-
Publication number: 20040254120Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.Type: ApplicationFiled: August 26, 2003Publication date: December 16, 2004Applicant: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Gattadahalli M. Anantharamaiah, Mohamad Navab
-
Publication number: 20040057871Abstract: This invention provides novel assays that are prognostic and/or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e.g. lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and/or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.Type: ApplicationFiled: June 5, 2003Publication date: March 25, 2004Applicant: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Mohamad Navab, Susan Hama